RESUMO
BACKGROUND: Involved or implicated in a wide spectrum of diseases, trypsin-like serine proteases comprise well studied drug targets and anti-targets that can be subdivided into two major classes. In one class there is a serine at position 190 at the S1 site, as in urokinase type plasminogen activator (urokinase or uPA) and factor VIIa, and in the other there is an alanine at 190, as in tissue type plasminogen activator (tPA) and factor Xa. A hydrogen bond unique to Ser190 protease-arylamidine complexes between O gamma(Ser190) and the inhibitor amidine confers an intrinsic preference for such inhibitors toward Ser190 proteases over Ala190 counterparts. RESULTS: Based on the structural differences between the S1 sites of Ser190 and Ala190 protease-arylamidine complexes, we amplified the selectivity of amidine inhibitors toward uPA and against tPA, by factors as high as 220-fold, by incorporating a halo group ortho to the amidine of a lead inhibitor scaffold. Comparison of K(i) values of such halo-substituted and parent inhibitors toward a panel of Ser190 and Ala190 proteases demonstrates pronounced selectivity of the halo analogs for Ser190 proteases over Ala190 counterparts. Crystal structures of Ser190 proteases, uPA and trypsin, and of an Ala190 counterpart, thrombin, bound by a set of ortho (halo, amidino) aryl inhibitors and of non-halo parents reveal the structural basis of the exquisite selectivity and validate the design principle. CONCLUSIONS: Remarkable selectivity enhancements of exceptionally small inhibitors are achieved toward the uPA target over the highly similar tPA anti-target through a single atom substitution on an otherwise relatively non-selective scaffold. Overall selectivities for uPA over tPA as high as 980-fold at physiological pH were realized. The increase in selectivity results from the displacement of a single bound water molecule common to the S1 site of both the uPA target and the tPA anti-target because of the ensuing deficit in hydrogen bonding of the arylamidine inhibitor when bound in the Ala190 protease anti-target.
Assuntos
Serina Endopeptidases/química , Inibidores de Serina Proteinase/síntese química , Animais , Sítios de Ligação , Cristalografia por Raios X , Desenho de Fármacos , Humanos , Ligação de Hidrogênio , Ligação Proteica , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Relação Estrutura-Atividade , Ativador de Plasminogênio Tecidual/antagonistas & inibidores , Ativador de Plasminogênio Tecidual/química , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidores , Ativador de Plasminogênio Tipo Uroquinase/química , Água/química , Água/metabolismoRESUMO
A nonselective inhibitor of trypsin-like serine proteases, 2-(2-hydroxybiphenyl-3-yl)-1H-indole-5-carboxamidine (1) (Verner, E.; Katz, B. A.; Spencer, J.; Allen, D.; Hataye, J.; Hruzewicz, W.; Hui, H. C.; Kolesnikov, A.; Li, Y.; Luong, C.; Martelli, A.; Radika. K.; Rai, R.; She, M.; Shrader, W.; Sprengeler, P. A.; Trapp, S.; Wang, J.; Young, W. B.; Mackman, R. L. J. Med. Chem. 2001, 44, 2753-2771) has been optimized through minor structural changes on the S1 binding group to afford remarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA). The trypsin-like serine proteases(1) that comprise drug targets can be broadly categorized into two subfamilies, those with Ser190 and those with Ala190. A single-atom modification, for example, replacement of hydrogen for chlorine at the 6-position of the 5-amidinoindole P1 group on 1, generated up to 6700-fold selectivity toward the Ser190 enzymes and against the Ala190 enzymes. The larger chlorine atom displaces a water molecule (H(2)O1(S1)) that binds near residue 190 in all the complexes of 1, and related inhibitors, in uPA, thrombin, and trypsin. The water molecule, H(2)O1(S1), in both the Ser190 or Ala190 enzymes, hydrogen bonds with the amidine N1 nitrogen of the inhibitor. When it is displaced, a reduction in affinity toward the Ala190 enzymes is observed due to the amidine N1 nitrogen of the bound inhibitor being deprived of a key hydrogen-bonding partner. In the Ser190 enzymes the affinity is maintained since the serine hydroxyl oxygen O gamma(Ser190) compensates for the displaced water molecule. High-resolution crystallography provided evidence for the displacement of the water molecule and validated the design rationale. In summation, a novel and powerful method for engineering selectivity toward Ser190 proteases and against Ala190 proteases without substantially increasing molecular weight is described.
Assuntos
Amidinas/síntese química , Indóis/síntese química , Inibidores de Proteases/síntese química , Serina Endopeptidases/química , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidores , Amidinas/química , Amidinas/farmacocinética , Amidinas/farmacologia , Sequência de Aminoácidos , Animais , Cristalografia por Raios X , Ligação de Hidrogênio , Indóis/química , Indóis/farmacocinética , Indóis/farmacologia , Masculino , Modelos Moleculares , Dados de Sequência Molecular , Inibidores de Proteases/química , Inibidores de Proteases/farmacocinética , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Ativador de Plasminogênio Tipo Uroquinase/química , Água/químicaRESUMO
The structure-based design and progression of a screening lead to a 3nM factor VIIa/TF inhibitor with improved selectivity versus related enzymes is described.
Assuntos
Amidinas/química , Amidinas/farmacologia , Fator VIIa/antagonistas & inibidores , Fenilacetatos/química , Fenilacetatos/farmacologia , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Amidinas/metabolismo , Sítios de Ligação , Cristalografia por Raios X , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Fator VIIa/química , Fator VIIa/metabolismo , Humanos , Ligação de Hidrogênio , Modelos Moleculares , Fenilacetatos/metabolismo , Tempo de Protrombina , Inibidores de Serina Proteinase/metabolismo , Relação Estrutura-AtividadeRESUMO
Novel scaffolds that bind to serine proteases through a unique network of short hydrogen bonds to the catalytic Ser195 have been developed. The resulting potent serine protease inhibitors were designed from lead molecule 2-(2-hydroxyphenyl)1H-benzoimidazole-5-carboxamidine, 6b, which is known to display several modes of binding. For instance, 6b can recruit zinc and bind in a manner similar to that reported by bis(5-amidino-2-benzimidazolyl)methane (BABIM) (Nature 1998, 391, 608-612).(1) Alternatively, 6b can bind in the absence of zinc through a multicentered network of short (<2.3 A) hydrogen bonds. The lead structure was optimized in the zinc-independent binding mode toward a panel of six human serine proteases to yield optimized inhibitors such as 2-(3-bromo-2-hydroxy-5-methylphenyl)-1H-indole-5-carboxamidine, 22a, and 2-(2-hydroxybiphenyl-3-yl)-1H-indole-5-carboxamidine, 22f. Structure-activity relationships determined that, apart from the amidine function, an indole or benzimidazole and an ortho substituted phenol group were also essential components for optimal potency. The affinities (K(i)) of 22a and 22f, for example, bearing these groups ranged from 8 to 600 nM toward a panel of six human serine proteases. High-resolution crystal structures revealed that the binding mode of these molecules in several of the enzymes was identical to that of 6b and involved short (<2.3 A) hydrogen bonds among the inhibitor hydroxyl oxygen, Ser195, and a water molecule trapped in the oxyanion hole. In summation, novel and potent trypsin-like serine protease inhibitors possessing a unique mode of binding have been discovered.
Assuntos
Amidinas/síntese química , Inibidores do Fator Xa , Indóis/síntese química , Inibidores de Serina Proteinase/síntese química , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidores , Amidinas/química , Sítios de Ligação , Cristalografia por Raios X , Humanos , Ligação de Hidrogênio , Indóis/química , Modelos Moleculares , Inibidores de Serina Proteinase/química , Espectrometria de Fluorescência , Espectrofotometria Ultravioleta , Relação Estrutura-AtividadeRESUMO
The development of potent and selective small molecule inhibitors of factor Xa is described.
Assuntos
Amidinas/farmacologia , Antitrombina III/síntese química , Antitrombina III/farmacologia , Indóis/farmacologia , Trombina/efeitos dos fármacos , Ativador de Plasminogênio Tipo Uroquinase/efeitos dos fármacos , Amidinas/química , Cristalografia , Desenho de Fármacos , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Fibrinolisina/efeitos dos fármacos , Indóis/química , Relação Estrutura-Atividade , Tripsina/efeitos dos fármacosRESUMO
A neutral inhibitor of the serine protease factor Xa was identified via a high-throughput screen of a commercial library. The initial lead 1 demonstrated reversible and competitive inhibition kinetics for factor Xa and possessed a high degree of selectivity versus other related serine proteases. Initial modeling efforts and the generation of a series of analogues of 1 are described.
Assuntos
Compostos de Anilina/farmacologia , Antitrombina III/metabolismo , Antitrombina III/farmacologia , Modelos Moleculares , Tiofenos/farmacologia , Trombina/efeitos dos fármacos , Ativador de Plasminogênio Tipo Uroquinase/efeitos dos fármacos , Compostos de Anilina/química , Compostos de Anilina/isolamento & purificação , Antitrombina III/síntese química , Antitrombina III/química , Domínio Catalítico/fisiologia , Avaliação Pré-Clínica de Medicamentos , Fibrinolisina/efeitos dos fármacos , Humanos , Programas de Rastreamento , Método de Monte Carlo , Conformação Proteica , Relação Estrutura-Atividade , Tiofenos/química , Tiofenos/isolamento & purificação , Tripsina/efeitos dos fármacosRESUMO
We describe a new serine protease inhibition motif in which binding is mediated by a cluster of very short hydrogen bonds (<2.3 A) at the active site. This protease-inhibitor binding paradigm is observed at high resolution in a large set of crystal structures of trypsin, thrombin, and urokinase-type plasminogen activator (uPA) bound with a series of small molecule inhibitors (2-(2-phenol)indoles and 2-(2-phenol)benzimidazoles). In each complex there are eight enzyme-inhibitor or enzyme-water-inhibitor hydrogen bonds at the active site, three of which are very short. These short hydrogen bonds connect a triangle of oxygen atoms comprising O(gamma)(Ser195), a water molecule co-bound in the oxyanion hole (H(2)O(oxy)), and the phenolate oxygen atom of the inhibitor (O6'). Two of the other hydrogen bonds between the inhibitor and active site of the trypsin and uPA complexes become short in the thrombin counterparts, extending the three-centered short hydrogen-bonding array into a tetrahedral array of atoms (three oxygen and one nitrogen) involved in short hydrogen bonds. In the uPA complexes, the extensive hydrogen-bonding interactions at the active site prevent the inhibitor S1 amidine from forming direct hydrogen bonds with Asp189 because the S1 site is deeper in uPA than in trypsin or thrombin. Ionization equilibria at the active site associated with inhibitor binding are probed through determination and comparison of structures over a wide range of pH (3.5 to 11.4) of thrombin complexes and of trypsin complexes in three different crystal forms. The high-pH trypsin-inhibitor structures suggest that His57 is protonated at pH values as high as 9.5. The pH-dependent inhibition of trypsin, thrombin, uPA and factor Xa by 2-(2-phenol)benzimidazole analogs in which the pK(a) of the phenol group is modulated is shown to be consistent with a binding process involving ionization of both the inhibitor and the enzyme. These data further suggest that the pK(a) of His57 of each protease in the unbound state in solution is about the same, approximately 6.8. By comparing inhibition constants (K(i) values), inhibitor solubilities, inhibitor conformational energies and corresponding structures of short and normal hydrogen bond-mediated complexes, we have estimated the contribution of the short hydrogen bond networks to inhibitor affinity ( approximately 1.7 kcal/mol). The structures and K(i) values associated with the short hydrogen-bonding motif are compared with those corresponding to an alternate, Zn(2+)-mediated inhibition motif at the active site. Structural differences among apo-enzymes, enzyme-inhibitor and enzyme-inhibitor-Zn(2+) complexes are discussed in the context of affinity determinants, selectivity development, and structure-based inhibitor design.
Assuntos
Serina Endopeptidases/química , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/metabolismo , Motivos de Aminoácidos , Ânions , Apoproteínas/química , Apoproteínas/metabolismo , Sítios de Ligação , Cristalografia por Raios X , Desenho de Fármacos , Fator Xa/química , Fator Xa/metabolismo , Ligação de Hidrogênio , Concentração de Íons de Hidrogênio , Modelos Moleculares , Fenóis/metabolismo , Conformação Proteica , Solubilidade , Eletricidade Estática , Especificidade por Substrato , Temperatura , Termodinâmica , Trombina/química , Trombina/metabolismo , Tripsina/química , Tripsina/metabolismo , Ativador de Plasminogênio Tipo Uroquinase/química , Ativador de Plasminogênio Tipo Uroquinase/metabolismo , Água/química , Água/metabolismo , Zinco/metabolismoRESUMO
Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin. Recently, both natural and synthetic factor Xa inhibitors have shown promising pharmacological effects in animal models of thrombosis. Accordingly, factor Xa has emerged as a compelling target for pharmacological intervention and much recent effort has focused on selective and potent inhibition of this key enzyme. Factor Xa and other enzymes in the coagulation cascade belong to the trypsin-like serine protease family, the various members of which are involved in numerous physiological functions in the body. Hence, to avoid toxicity and adverse side effects, it is important to selectively inhibit the target enzyme. Achieving the needed selectivity has proved challenging due to the high degree of structural homology around the active site of this class of enzymes. This article provides a brief review of the strategies currently being employed to develop oral anticoagulants and, more specifically, the structural features of protein-ligand binding that have been utilized to achieve potency and selectivity toward factor Xa. Additionally, selected lead molecules will be discussed to highlight binding motifs used to attain both potency and selectivity in drug candidates.
Assuntos
Anticoagulantes/farmacologia , Inibidores do Fator Xa , Animais , Anticoagulantes/uso terapêutico , Transtornos da Coagulação Sanguínea/tratamento farmacológico , Fator Xa/química , HumanosRESUMO
[reaction: see text] A pyrrolinone-based hydroxamate matrix metalloprotease inhibitor, (-)-1, has been designed and synthesized. Enzymatic assay revealed that (-)-1 inhibited three of the ten matrix metalloprotease enzymes examined and as such represents a new, potentially important lead structure.
Assuntos
Metaloendopeptidases/antagonistas & inibidores , Inibidores de Proteases/síntese química , Pirróis/síntese química , Aldeídos , Desenho de Fármacos , Isoenzimas/antagonistas & inibidores , Metaloendopeptidases/química , Modelos Moleculares , Inibidores de Proteases/química , Pirróis/químicaRESUMO
BACKGROUND: Urokinase-type plasminogen activator (uPA) is a protease associated with tumor metastasis and invasion. Inhibitors of uPA may have potential as drugs for prostate, breast and other cancers. Therapeutically useful inhibitors must be selective for uPA and not appreciably inhibit the related, and structurally and functionally similar enzyme, tissue-type plasminogen activator (tPA), involved in the vital blood-clotting cascade. RESULTS: We produced mutagenically deglycosylated low molecular weight uPA and determined the crystal structure of its complex with 4-iodobenzo[b]thiophene 2-carboxamidine (K(i) = 0.21 +/- 0.02 microM). To probe the structural determinants of the affinity and selectivity of this inhibitor for uPA we also determined the structures of its trypsin and thrombin complexes, of apo-trypsin, apo-thrombin and apo-factor Xa, and of uPA, trypsin and thrombin bound by compounds that are less effective uPA inhibitors, benzo[b]thiophene-2-carboxamidine, thieno[2,3-b]-pyridine-2-carboxamidine and benzamidine. The K(i) values of each inhibitor toward uPA, tPA, trypsin, tryptase, thrombin and factor Xa were determined and compared. One selectivity determinant of the benzo[b]thiophene-2-carboxamidines for uPA involves a hydrogen bond at the S1 site to Ogamma(Ser190) that is absent in the Ala190 proteases, tPA, thrombin and factor Xa. Other subtle differences in the architecture of the S1 site also influence inhibitor affinity and enzyme-bound structure. CONCLUSIONS: Subtle structural differences in the S1 site of uPA compared with that of related proteases, which result in part from the presence of a serine residue at position 190, account for the selectivity of small thiophene-2-carboxamidines for uPA, and afford a framework for structure-based design of small, potent, selective uPA inhibitors.
Assuntos
Amidinas/química , Tiofenos/química , Ativador de Plasminogênio Tipo Uroquinase/química , Sítios de Ligação , Desenho de Fármacos , Fator Xa/química , Glicosilação , Ligação de Hidrogênio , Concentração de Íons de Hidrogênio , Cinética , Modelos Moleculares , Dados de Sequência Molecular , Proteínas Recombinantes/química , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/uso terapêutico , Especificidade por Substrato , Trombina/química , Ativador de Plasminogênio Tecidual/química , Tripsina/química , Ativador de Plasminogênio Tipo Uroquinase/antagonistas & inibidoresRESUMO
The molecular modeling, synthesis, and elucidations of the solid state and solution structures of N-methylated 3,5-linked bispyrrolin-4-ones are described. Prior investigations established that the 3,5-linked pyrrolin-4-one based scaffold can be incorporated into mimics of beta-sheet/beta-strands and into potent, orally bioavailable inhibitors of the HIV-1 protease. To extend the utility of this scaffold beyond that of the initially designed mimics of beta-sheet/beta-strands, we have now explored the structure of N-methylated pyrrolinones. Molecular modeling indicated that N-methylated bispyrrolinones could adopt three low-energy backbone conformations (ca. 165 degrees, 289 degrees, and 320 degrees). Upon their successful synthesis, structural elucidation both in the solid state and in solution revealed the existence of two of the three predicted backbone conformers (ca. 165 degrees and 289 degrees). Two structures were particularly noteworthy and completely unexpected. Mono-N-methyl bispyrrolinone (+)-1 self assembled in the solid state to form a novel helix, while the acetylene-linked dimer of (+)-1, designed to potentiate the observed helical array, instead associated via an intermolecular hydrogen bond in parallel columns. These serendipitous observations led us to speculate that the pyrrolinone moiety may in fact represent a privileged nonpeptide scaffold, able to mimic not only the extended beta-sheet/beta-strand conformation as initially targeted, but also diverse conformations including those analogous to beta-turns and helices. These seemingly unlimited conformations greatly expand the scope of this scaffold for the development of low-molecular weight ligands for biologically important macromolecules.
Assuntos
Modelos Moleculares , Pirróis/química , Pirrolidinonas/química , Cristalografia por Raios X , Inibidores da Protease de HIV/química , Espectroscopia de Ressonância Magnética , Conformação Molecular , Estrutura Molecular , Estrutura Secundária de Proteína , EspectrofotometriaRESUMO
In recent years, a role for the mast cell has emerged as a multifunctional, key effector cell in the immune system and may also serve to modulate the inflammatory response and immune-nervous system interactions. Mast cell stimulation leads to the secretion of several classes of mediators including proteolytic enzymes, most notably the trypsin-like serine proteinase, tryptase. Recent immunological and biological studies have demonstrated an association of mast cells and tryptase activity with a broad range of allergic and inflammatory conditions affecting nearly all the major systems of the human body. At present, there is sufficient evidence to strongly suggest that tryptase activity is a key aspect of some common and serious allergic and inflammatory diseases, particularly asthma. Due to the increasing prevalence of asthma in industrialized society, the inhibition of tryptase is viewed as a potentially important and novel therapeutic mechanism for disease intervention. Recent advances in the design of potent and selective inhibitors of tryptase provide a great deal of promise for the development of safe and effective drugs for the treatment of asthma and possibly a range of other diseases in the early 21st century.
RESUMO
PURPOSE: To compare the permeation characteristics of amide bond-containing HIV-1 protease inhibitors and their pyrrolinone-containing counterparts across Caco-2 cell monolayers, a model of the intestinal mucosa. METHODS: Transepithelial transport and cellular uptake of three pairs of amide bond-containing and pyrrolinone-based peptidomimetics were assessed in the presence and absence of cyclosporin A using the Caco-2 cell culture model. The potential of the peptidomimetics to interact with biological membranes was estimated by IAM chromatography. RESULTS: In the absence of cyclosporin A, apical (AP) to basolateral (BL) flux of all compounds studied was less than the flux determined in the opposite direction (i.e., BL-to-AP). The ratio of the apparent permeability coefficients (Papp) calculated for the BL-to-AP and AP-to-BL transport (P(BL-->AP)/P(AP-->BL)) varied between 1.7 and 36.2. When individual pairs were ompared, P(BL-->AP)/P(AP-BL) ratios of the pyrrolinone-containing compounds were 1.5 to 11.5 times greater than those determined for the amide bond-containing analogs. Addition of 25 microM cyclosporin A to the transport buffer reduced the P(BL-->AP)/P(AP-->BL) ratios for all protease inhibitors to a value close to unity. Under these conditions, the amide bond-containing peptidomimetics were at least 1.6 to 2.8 times more able to permeate Caco-2 cell monolayers than were the pyrrolinone-containing compounds. The intrinsic uptake characteristics into Caco-2 cells determined in the presence of 25 microM cyclosporin A were slightly greater for the amide bond-containing protease inhibitors than for the pyrrolinone-containing analogs. These uptake results are consistent with the transepithelial transport results determined across this in vitro model of the intestinal mucosa. CONCLUSIONS: The amide bond-containing and pyrrolinone-based peptidomimetics are substrates for apically polarized efflux systems present in Caco-2 cell monolayers. The intrinsic permeabilities of the amide bond-containing protease inhibitors are slightly greater than the intrinsic permeabilities of the pyrrolinone-based analogs through Caco-2 cell monolayers.
Assuntos
Células CACO-2/metabolismo , Inibidores da Protease de HIV/farmacocinética , Mimetismo Molecular , Peptídeos/farmacocinética , Transporte Biológico , Células CACO-2/fisiologia , Permeabilidade da Membrana Celular , Cromatografia Líquida de Alta Pressão , Inibidores da Protease de HIV/química , Humanos , Peptídeos/químicaRESUMO
We show that carbohydrates constitute an attractive source of readily available, stereochemically defined scaffolds for the facile attachment of side chains contained in genetically encoded and other amino acids. beta-D- and beta-L-glucose, L-mannose, and the 6-deoxy-6-N-analogue of beta-D-glucose have been employed to synthesize peptidomimetics that bind the SRIF receptors on AtT-20 mouse pituitary cells, five cloned human receptor subtypes (hSSTRs), and the NK-1 receptor. The affinity profile of various sugar-based ligands at the hSSTRs is compared with that of SRIF. Compound 19 bound hSSTR4 with a Ki of 100 nM. Subtle structural changes affect affinities. Evidence is presented that suggests that one compound (8) binds both the AtT-20 cell receptors and the five hSSTRs via a unique mode. The SARs of the glycosides at SRIF receptors differ markedly from those at the NK-1 receptor. For example a 4-benzyl substituent is important for SRIF receptor binding, but the 4-desbenzyl analogue 27 was highly potent (IC50 of 27 nM) at the NK-1 receptor. A new, nonbasic method for the synthesis of base-sensitive ethers from primary and secondary alcohols is also described.
Assuntos
Éteres/metabolismo , Glucosídeos/metabolismo , Mimetismo Molecular , Monossacarídeos/metabolismo , Receptores de Superfície Celular/metabolismo , Receptores de Somatostatina/agonistas , Animais , Células CHO , Linhagem Celular , Cricetinae , Éteres/síntese química , Éteres/química , Glucosídeos/síntese química , Glucosídeos/química , Humanos , Ligantes , Lisina/metabolismo , Camundongos , Modelos Moleculares , Monossacarídeos/síntese química , Monossacarídeos/química , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/metabolismo , Hipófise/citologia , Hipófise/metabolismo , Receptores da Neurocinina-1/metabolismo , Somatostatina/análogos & derivados , Somatostatina/química , Somatostatina/metabolismo , Estereoisomerismo , Relação Estrutura-AtividadeAssuntos
Antivirais/química , Inibidores da Protease de HIV/química , Protease de HIV/metabolismo , Pirróis/química , Administração Oral , Antivirais/administração & dosagem , Antivirais/farmacocinética , Disponibilidade Biológica , Cristalografia por Raios X , Dipeptídeos/administração & dosagem , Dipeptídeos/química , Dipeptídeos/farmacocinética , Desenho de Fármacos , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/farmacocinética , Ligação de Hidrogênio , Indinavir/química , Indóis/administração & dosagem , Indóis/química , Indóis/farmacocinética , Modelos Moleculares , Peso Molecular , Conformação Proteica , Pirróis/administração & dosagem , Pirróis/farmacocinéticaRESUMO
The de novo design and initial synthetic studies directed toward construction of a novel non-peptide scaffold for beta-strand/sheet and related secondary peptide structural mimics are described. The scaffold, consisting of a repeating array of 2,5,5-trisubstituted pyrrolinone (enaminone) units punctuated with appropriate amino acid side chains, is conceptually related to our previously successful 3,5-linked polypyrrolinone non-peptide peptidomimetic scaffold. Construction of the 2,5,5-trisubstituted pyrrolinone ring system proceeds via intramolecular condensation of an N-protected amino dione. The latter is prepared from a protected alpha-amino ketone and aldehyde via an aldol-oxidation reaction sequence.
Assuntos
Inibidores da Protease de HIV/síntese química , Pirróis/química , Cristalografia por Raios X , Modelos Moleculares , Conformação Proteica , Estrutura Secundária de ProteínaRESUMO
The endogenous peptides somatostatin (SRIF) and substance P comprise very different structures. Although both bind G-protein-coupled receptors, the SRIF receptors (SSTR 1-5) recognize SRIF and related peptides which retain its beta-turn such as the potent cyclic hexapeptide SRIF agonist L-363,301 (6a), but not substance P. Conversely the NK-1 receptor binds substance P but not the above ligands. In contrast, the beta-D-glucosides 1 and 2, designed to mimic the beta-turn of 6a, bind both receptors. This observation led us to attempt the conversion of 6a into the first potent, selective cyclic hexapeptide ligand for the NK-1 receptor. To this end, we combined design with a minilibrary approach. The goal was accomplished with surprising ease, leading to the NK-1 receptor antagonist 9 (IC50 2.0 +/- 0.4 nM). This demonstrates that peptidomimetics, incorporating in this case the promiscuous beta-D-glucose scaffold, can provide valuable clues about receptor similarities not revealed by their endogenous ligands. In addition, this work suggests that the use of libraries and rational design need not be mutually exclusive approaches to lead discovery.
Assuntos
Glucosídeos/síntese química , Antagonistas dos Receptores de Neurocinina-1 , Oligopeptídeos/síntese química , Peptídeos Cíclicos/síntese química , Sequência de Aminoácidos , Cromatografia Líquida de Alta Pressão , Desenho de Fármacos , Glucosídeos/química , Glucosídeos/metabolismo , Glucosídeos/farmacologia , Fosfatos de Inositol/antagonistas & inibidores , Fosfatos de Inositol/biossíntese , Ligantes , Espectroscopia de Ressonância Magnética , Dados de Sequência Molecular , Estrutura Molecular , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Oligopeptídeos/farmacologia , Peptídeos Cíclicos/química , Peptídeos Cíclicos/metabolismo , Peptídeos Cíclicos/farmacologia , Receptores da Neurocinina-1/metabolismo , Receptores de Somatostatina/metabolismo , Somatostatina/farmacologia , Substância P/metabolismo , Substância P/farmacologiaRESUMO
The desire to replace the amide backbone of renin inhibitors with a new scaffold led us to explore vinylogous amides (enaminones). An initial attempt proved unsuccessful, a result explained after the fact via docking experiments. Based on this lesson, we designed a different vinylogous amide scaffold which incorporated one or more pyrrolinone rings into the backbone. Three of the four compounds gave IC50S in the 0.6 to 18 microM range. These compounds did not inhibit HIV-1 protease. Taken together, the results reported herein provide insights into the role of hydrogen bonding and steric interactions for binding to renin.
Assuntos
Peptídeos/síntese química , Renina/antagonistas & inibidores , Desenho de Fármacos , Ligação de Hidrogênio , Conformação ProteicaRESUMO
Monoclonal antibodies, induced with a phosphonate diester hapten, catalyzed the coupling of p-nitrophenyl esters of N-acetyl valine, leucine, and phenylalanine with tryptophan amide to form the corresponding dipeptides. All possible stereoisomeric combinations of the ester and amide substrates were coupled at comparable rates. The antibodies did not catalyze the hydrolysis of the dipeptide product nor hydrolysis or racemization of the activated esters. The yields of the dipeptides ranged from 44 to 94 percent. The antibodies were capable of multiple turnovers at rates that exceeded the rate of spontaneous ester hydrolysis. This achievement suggests routes toward creating a small number of antibody catalysts for polypeptide syntheses.